{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:40:22Z","timestamp":1788172822286,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health","award":["U54EB007958"],"award-info":[{"award-number":["U54EB007958"]}]},{"name":"National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health","award":["U54EB007958"],"award-info":[{"award-number":["U54EB007958"]}]},{"name":"National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health","award":["U54EB007958"],"award-info":[{"award-number":["U54EB007958"]}]},{"name":"National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health","award":["U54EB007958"],"award-info":[{"award-number":["U54EB007958"]}]},{"name":"National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health","award":["U54EB007958"],"award-info":[{"award-number":["U54EB007958"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Ugandan men with urethral discharge syndrome (UDS) have high burdens of curable sexually transmitted infections (STIs) and HIV. STI complaints are treated syndromically, but post-treatment symptom resolution (SR) data are lacking in this group. This study estimated the time from treatment to symptom resolution (TTR) and examined associations with sociodemographic and behavioral factors and TTR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>250 men with UDS were recruited at health centers in Kampala, Uganda. Participants underwent point-of-care testing for HIV\/syphilis, and urogenital samples were retrospectively analyzed for <jats:italic>Chlamydia trachomatis<\/jats:italic> (CT), <jats:italic>Neisseria gonorrhoeae<\/jats:italic> (NG), <jats:italic>Mycoplamsa genitalium<\/jats:italic> (MG), and <jats:italic>Trichomonas vaginalis<\/jats:italic> (TV) using Aptima nucleic acid amplification tests (Hologic Inc., Marlborough, MA, USA). Socio-behavioral data were collected by questionnaire. Participants received follow-up calls at 14-, and 21-days post-enrollment to assess SR, antibiotic adherence, and sexual behaviors. Differences between participants by SR at day 14 were determined by Fisher Exact test, Wilcoxon rank-sum test, Chi-squared test, and Welch\u2019s t-test as appropriate. Univariable and multivariable accelerated failure time (AFT) models were used to identify associations between participant factors and TTR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 239 (95.6%) participants who completed day 14 follow-up surveys, 37 (16%) did not have SR by 14-days post-enrollment and treatment initiation. Median (IQR) TTR was 4.0 (3.0,6.0) days. Delayed TTR was associated with previous episodes of UDS in the prior six months (2.0 vs. 1.4, <jats:italic>p<\/jats:italic>\u2009=\u20090.010) and negative tests for CT\/NG\/MG\/TV (35% vs. 15%, <jats:italic>p<\/jats:italic>\u2009=\u20090.004). These relationships held true when controlling for potential confounders including prior antimicrobial use, possible reinfection following sexual exposures post-enrollment, treatment non-adherence, HIV status, and other behaviors associated with increased vulnerabilities to STIs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Delayed TTR was associated with prior UDS episodes. Negative tests for common curable STIs were associated with delayed TTR suggesting the possible role of other infectious or non-infectious etiologies. The underlying mechanisms of delayed SR, e.g., reinfection, treatment failure, or dysregulated mucosal immunity, warrant further exploration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12879-025-11196-8","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T17:58:37Z","timestamp":1749405517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-treatment time to symptom resolution and associated factors in a cohort of Ugandan men with urethral discharge syndrome"],"prefix":"10.1186","volume":"25","author":[{"given":"Courtney","family":"Pasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Gough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annet","family":"Onzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Parkes-Ratanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan H.","family":"Melendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kyambadde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari C.","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.","family":"Hamill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"key":"11196_CR1","unstructured":"Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 20162019 6\/21\/2019:[1\u201343 pp.]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31384073"},{"issue":"4","key":"11196_CR2","doi-asserted-by":"publisher","first-page":"e0196209","DOI":"10.1371\/journal.pone.0196209","volume":"13","author":"NJ Garrett","year":"2018","unstructured":"Garrett NJ, Osman F, Maharaj B, Naicker N, Gibbs A, Norman E, et al. Beyond syndromic management: opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries. PLoS ONE. 2018;13(4):e0196209.","journal-title":"PLoS ONE"},{"issue":"Suppl 6","key":"11196_CR3","doi-asserted-by":"publisher","first-page":"e25355","DOI":"10.1002\/jia2.25355","volume":"22","author":"MS Cohen","year":"2019","unstructured":"Cohen MS, Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. J Int AIDS Soc. 2019;22(Suppl 6):e25355.","journal-title":"J Int AIDS Soc"},{"key":"11196_CR4","doi-asserted-by":"crossref","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually Transmitted Infections Treat Guidelines 2021 MMWR Recomm Rep. 2021;70(4):1\u2013187.","DOI":"10.15585\/mmwr.rr7004a1"},{"issue":"Suppl 1","key":"11196_CR5","doi-asserted-by":"publisher","first-page":"i145","DOI":"10.1136\/sti.78.suppl_1.i145","volume":"78","author":"AM Jolly","year":"2002","unstructured":"Jolly AM, Wylie JL. Gonorrhoea and chlamydia core groups and sexual networks in Manitoba. Sex Transm Infect. 2002;78(Suppl 1):i145\u201351.","journal-title":"Sex Transm Infect"},{"issue":"10","key":"11196_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/OLQ.0000000000000489","volume":"43","author":"PJ Kissinger","year":"2016","unstructured":"Kissinger PJ, White S, Manhart LE, Schwebke J, Taylor SN, Mena L, et al. Azithromycin treatment failure for Chlamydia trachomatis among heterosexual men with nongonococcal urethritis. Sex Transm Dis. 2016;43(10):599\u2013602.","journal-title":"Sex Transm Dis"},{"issue":"1","key":"11196_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/0956462419886775","volume":"31","author":"H Fifer","year":"2020","unstructured":"Fifer H, Saunders J, Soni S, Sadiq ST, FitzGerald M. 2018 UK National guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS. 2020;31(1):4\u201315.","journal-title":"Int J STD AIDS"},{"issue":"1","key":"11196_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/infdis\/172.1.186","volume":"172","author":"KH Ramsey","year":"1995","unstructured":"Ramsey KH, Schneider H, Cross AS, Boslego JW, Hoover DL, Staley TL, et al. Inflammatory cytokines produced in response to experimental human gonorrhea. J Infect Dis. 1995;172(1):186\u201391.","journal-title":"J Infect Dis"},{"issue":"1","key":"11196_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12879-020-05197-y","volume":"20","author":"M Martin-Sanchez","year":"2020","unstructured":"Martin-Sanchez M, Ong JJ, Fairley CK, Chen MY, Williamson DA, Maddaford K, et al. Clinical presentation of asymptomatic and symptomatic heterosexual men who tested positive for urethral gonorrhoea at a sexual health clinic in melbourne, Australia. BMC Infect Dis. 2020;20(1):486.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"11196_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00007435-199505000-00002","volume":"22","author":"J Haizlip","year":"1995","unstructured":"Haizlip J, Isbey SF, Hamilton HA, Jerse AE, Leone PA, Davis RH, Cohen MS. Time required for elimination of Neisseria gonorrhoeae from the urogenital tract in men with symptomatic urethritis: comparison of oral and intramuscular single-dose therapy. Sex Transm Dis. 1995;22(3):145\u20138.","journal-title":"Sex Transm Dis"},{"issue":"11","key":"11196_CR11","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/cid\/ciw141","volume":"62","author":"CM Wind","year":"2016","unstructured":"Wind CM, van der Schim MF, Unemo M, Schuurman R, van Dam AP, de Vries HJC. Test of cure for anogenital gonorrhoea using modern RNA-Based and DNA-Based nucleic acid amplification tests: A prospective cohort study. Clin Infect Dis. 2016;62(11):1348\u201355.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"11196_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/infdis\/169.3.532","volume":"169","author":"MS Cohen","year":"1994","unstructured":"Cohen MS, Cannon JG, Jerse AE, Charniga LM, Isbey SF, Whicker LG. Human experimentation with Neisseria gonorrhoeae: rationale, methods, and implications for the biology of infection and vaccine development. J Infect Dis. 1994;169(3):532\u20137.","journal-title":"J Infect Dis"},{"issue":"10","key":"11196_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1097\/OLQ.0000000000001040","volume":"46","author":"LC Chambers","year":"2019","unstructured":"Chambers LC, Hughes JP, Glick SN, Morgan JL, Lowens MS, Robinson TS, et al. Resolution of symptoms and resumption of sex after diagnosis of nongonococcal urethritis among men who have sex with men. Sex Transm Dis. 2019;46(10):676\u201382.","journal-title":"Sex Transm Dis"},{"issue":"1","key":"11196_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12879-022-07431-1","volume":"22","author":"MM Hamill","year":"2022","unstructured":"Hamill MM, Onzia A, Wang TH, Kiragga AN, Hsieh YH, Parkes-Ratanshi R, et al. High burden of untreated syphilis, drug resistant Neisseria gonorrhoeae, and other sexually transmitted infections in men with urethral discharge syndrome in kampala, Uganda. BMC Infect Dis. 2022;22(1):440.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"11196_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/sextrans-2020-054581","volume":"97","author":"F Kakooza","year":"2021","unstructured":"Kakooza F, Musinguzi P, Workneh M, Walwema R, Kyambadde P, Mande E, et al. Implementation of a standardised and quality-assured enhanced gonococcal antimicrobial surveillance programme in accordance with WHO protocols in kampala, Uganda. Sex Transm Infect. 2021;97(4):312\u20136.","journal-title":"Sex Transm Infect"},{"key":"11196_CR16","unstructured":"Uganda Clinical Guidelines. 2016: National Guidelines for Management of Common Conditions. Uganda 2016. pp. 269\u2013\u200976."},{"key":"11196_CR17","doi-asserted-by":"crossref","unstructured":"Beck EJ, Laeyendecker O, Saraf S, Ashokkumar S, Onzia A, Melendez JH et al. High level of HIV viral suppression in a cross-sectional study of Ugandan men with urethritis and bacterial STI. Int J STD AIDS. 2023:9564624231193491.","DOI":"10.1177\/09564624231193491"},{"issue":"1","key":"11196_CR18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1186\/s12879-016-1878-3","volume":"16","author":"CM Wind","year":"2016","unstructured":"Wind CM, van der Schim MF, Unemo M, Schuurman R, van Dam AP, de Vries HJ. Time to clearance of Chlamydia trachomatis RNA and DNA after treatment in patients coinfected with Neisseria gonorrhoeae - a prospective cohort study. BMC Infect Dis. 2016;16(1):554.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"11196_CR19","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1128\/JCM.40.10.3596-3601.2002","volume":"40","author":"LH Bachmann","year":"2002","unstructured":"Bachmann LH, Desmond RA, Stephens J, Hughes A, Hook EW. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. J Clin Microbiol. 2002;40(10):3596\u2013601.","journal-title":"J Clin Microbiol"},{"key":"11196_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1177\/009286150203600312","volume":"36","author":"R Kay","year":"2002","unstructured":"Kay R, Kinnersley N. On the use of the accelerated failure time model as an alternative to the proportional hazards model in the treatment of time to event data: A case study in influenza. Drug Inf J. 2002;36:571\u20139.","journal-title":"Drug Inf J"},{"issue":"4","key":"11196_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/aje\/kws412","volume":"177","author":"D Westreich","year":"2013","unstructured":"Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol. 2013;177(4):292\u20138.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"11196_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/sextrans-2020-054626","volume":"97","author":"O Ayinde","year":"2021","unstructured":"Ayinde O, Ross JDC. Time to resolution of genital symptoms for uncomplicated gonorrhoea: a prospective cohort study. Sex Transm Infect. 2021;97(5):368\u201374.","journal-title":"Sex Transm Infect"},{"key":"11196_CR23","doi-asserted-by":"publisher","first-page":"1248613","DOI":"10.3389\/fimmu.2023.1248613","volume":"14","author":"T Belcher","year":"2023","unstructured":"Belcher T, Rollier CS, Dold C, Ross JDC, MacLennan CA. Immune responses to Neisseria gonorrhoeae and implications for vaccine development. Front Immunol. 2023;14:1248613.","journal-title":"Front Immunol"},{"issue":"4","key":"11196_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1258\/ijsa.2009.009235","volume":"21","author":"T Fowler","year":"2010","unstructured":"Fowler T, Caley M, Johal R, Brown R, Ross JD. Previous history of gonococcal infection as a risk factor in patients presenting with gonorrhoea. Int J STD AIDS. 2010;21(4):277\u20138.","journal-title":"Int J STD AIDS"},{"issue":"11","key":"11196_CR25","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1128\/JCM.01903-06","volume":"44","author":"V Manchanda","year":"2006","unstructured":"Manchanda V, Bhalla P. Emergence of non-ceftriaxone-susceptible Neisseria meningitidis in India. J Clin Microbiol. 2006;44(11):4290\u20131.","journal-title":"J Clin Microbiol"},{"issue":"8","key":"11196_CR26","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1093\/jac\/dkad193","volume":"78","author":"F Kakooza","year":"2023","unstructured":"Kakooza F, Golparian D, Matoga M, Maseko V, Lamorde M, Krysiak R, et al. Genomic surveillance and antimicrobial resistance determinants in Neisseria gonorrhoeae isolates from uganda, Malawi and South africa, 2015-20. J Antimicrob Chemother. 2023;78(8):1982\u201391.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"11196_CR27","doi-asserted-by":"publisher","first-page":"e0230421","DOI":"10.1128\/spectrum.02304-21","volume":"10","author":"JH Melendez","year":"2022","unstructured":"Melendez JH, Hardick J, Onzia A, Yu T, Kyambadde P, Parkes-Ratanshi R, et al. Retrospective analysis of Ugandan men with urethritis reveals Mycoplasma genitalium and associated macrolide resistance. Microbiol Spectr. 2022;10(2):e0230421.","journal-title":"Microbiol Spectr"},{"issue":"5","key":"11196_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/jdv.17972","volume":"36","author":"JS Jensen","year":"2022","unstructured":"Jensen JS, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M. 2021 European guideline on the management of Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2022;36(5):641\u201350.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"11196_CR29","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1093\/jac\/dkv246","volume":"70","author":"L Falk","year":"2015","unstructured":"Falk L, Enger M, Jensen JS. Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women. J Antimicrob Chemother. 2015;70(11):3134\u201340.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11196-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T17:58:38Z","timestamp":1749405518000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11196-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11196"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11196-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,8]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In Uganda, the Joint Clinical Research Center at Makerere University (JC0919), and the Ugandan National Council for Science and Technology (HS455ES) approved the study. Additionally, the Johns Hopkins Institutional Review Board (IRB00215298) approved the study protocol. No study procedures were commenced until written informed consent had been obtained in either Luganda or English.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"801"}}